| NEKTAR THERAPEUTICS |
| USA |
| Gesundheit |
| US6402683063 / A419UB |
| ITH0 (Frankfurt) / NKTR (NASDAQ) |
| FRA:ITH0, ETR:ITH0, ITH0:GR, NASDAQ:NKTR |
| - |
| https://www.nektar.com/ |
|
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing immunology and oncology medicines. Nektar Therapeutics’ current pipeline centers on therapies designed to address immune system dysfunction in a..
>Volltext.. |
| 1162.85 Mio. EUR |
| 679.71 Mio. EUR |
| 49.21 Mio. EUR |
| -117.15 Mio. EUR |
| -141.65 Mio. EUR |
| -6.04 EUR |
| 122.54 Mio. EUR |
| 35.26 Mio. EUR |
| -210.76 Mio. EUR |
| 9.64 |
| -24.86% |
| -32.55% |
| - |
| - |
| - |
| - |
| NEKTAR THERAPEUTICS, NEKTAR THERAPEUTIC |
| 13.11.26 |
|